by McKesson Ventures | Oct 19, 2022 | Portfolio News
Cancer has managed to be the most expensive condition increasing employers’ costs. Seeing this issue as an opportunity to collaborate Carrum Health and GRAIL have teamed up to create a solution. Carrum Health is a value-based platform that helps employers and...
by McKesson Ventures | Sep 23, 2021 | Press Releases
The National Health Service (NHS) in the United Kingdom has announced the world’s largest trial of GRAIL’s Galleri blood test, which was developed to detect more than 50 types of cancer before symptoms appear. The NHS hopes to recruit 140,000 volunteers across the UK...
by McKesson Ventures | Sep 17, 2021 | Portfolio News
The University of Oxford has opened a new study, which will trial a new multi-cancer early detection (MCED) blood test for early detection of more than 50 types of cancer. The study, SYMPLIFY, is also open at Oxford University Hospitals (OUH) and already includes more...
by McKesson Ventures | Jun 15, 2021 | Portfolio News
GRAIL, the developer of multi-cancer early detection test Galleri, is building on its earlier commercial partnership with the UK’s National Health Service. That partnership aims to confirm Galleri’s clinical and economic performance in the UK healthcare system, which...
by McKesson Ventures | Mar 16, 2021 | Press Releases
GRAIL has announced that it is joining forces with AccessHope™ to offer a world-class service experience to people who use Galleri™, GRAIL’s first-of-kind multi-cancer early detection blood test. This collaboration is part of GRAIL’s effort to help patients and their...
